drugset / Trial / NCT01056276
Study to Evaluate the Combination of Bendamustine, Bortezomib and Dexamethasone (BBD) in the First-Line Treatment of Patients With Multiple Myeloma Who Are Not Candidates for High Dose Chemotherapy
Phase 2
Completed
59 enrolled
SCRI Development Innovations, LLC
Cephalon · collabMillennium Pharmaceuticals, Inc. · collab
NaSingle-groupOpen-labelTreatment
Summary
In this study, investigators will evaluate the activity of bendamustine, bortezomib and dexamethasone (BBD). This regimen combines 3 agents with high activity in multiple myeloma, with different mechanisms of action and non-overlapping toxicities.
Timeline
- Start
- 2010-05
- Primary completion
- 2015-08
- Completion
- 2017-02
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Bendamustine | Small molecule | 80 mg/m2 | Intravenous |
| Subject | Bortezomib | Small molecule | 1.3 mg/m2 | Intravenous |
| Subject | Dexamethasone | Small molecule | 20 mg | Oral |